News

Pilar Santisteban appointed member of the Technical Scientific Committee of the State Research Agency

On April 30, Pilar Santisteban has been appointed member of the Technical Scientific Committee of the AEI. The proposal made by the Governing Committee of the Agency, is part of the consolidation phase of the Agency, where the scientific advice of the Committee will be essential.   The agency has a Director elected in Public Contest, and has established its new structure by developing autonomous administrative capacities. The director, with the advice of the Scientific and Technical Committee, is beginning to develop calls under the new organization. Participation in the Scientific Committee of our colleague is a pride for the institute and we take advantage of this platform to congratulate Pilar for her appointment.  

Engineered immune cells produce antibodies to fight HIV

Engineered immune cells produce antibodies to fight HIV   B cells that are removed from patients' bloodstreams and genetically altered may one day allow more effective vaccines for HIV, influenza and hepatitis   Alicia González Martín, principal investigator of the Institute for Biomedical Research Alberto Sols (IIBm-CSIC/UAM), has co-developed with James Voss, Raiees Andrabi and Dennis Burton from The Scripps Research Institute of California a new technique to engineer human primary B cells to produce antibodies that can neutralize, or disable, human immunodeficiency virus (HIV). This new technique could one day be used to generate new, broadly acting vaccines or therapies against not only HIV but other pathogens such as influenza and hepatitis. The study entitled: "Reprogramming the antigen specificity of B cells using...

The Fero Foundation has awarded Dr. Bruno Sainz, Head of the Cancer Stem Cells and Tumor Microenvironment Group of Biomedical Research Institute “Alberto Sols”

The Fero Foundation has awarded Dr. Bruno Sainz, Head of the Cancer Stem Cells and Tumor Microenvironment Group of Biomedical Research Institute "Alberto Sols" of the Autonomous University of Madrid (UAM), with the distinguished Fero Research Grant for his translational research project in oncology. The Foundation has awarded Dr. Sainz both for his strong career path and for the strength of his proposal, a promising approach that has the ultimate goal of fighting pancreatic cancer by identifying new therapeutic targets associated with cancer stem cells, which represent between 1 and 5% of the total tumor mass. In addition, this year and for the first time there have been two projects awarded in the fifteenth celebration of the Fero Research Grant awards, which took place on December 3, 2018 at the Westin Palace in Madrid. The other winner was Dr....

L'Oréal-UNESCO For Women in Science Awards 2018

Alicia González Martín, a principal investigator in the Biomedical Research Institute Alberto Sols (IIBm-CSIC/UAM), was one of the 5 young scientist that received the L'Oréal-UNESCO For Women in Science Award in its 13th edition. The award took into consideration her scientific trajectory as well as the proposed project "New regulators of immune tolerance and autoimmune diseases".   The L'Oréal-UNESCO For Women in Science program has been working for 20 years to increase the visibility of women in sciences and to inspire scientific careers in girls and young women. It has recognized the accomplishments of outstanding female scientists worldwide and promoted the visibility of their work, making them a reference for future generations.   November 28th, 2018 - Madrid

Dr. Belén Peral´s research group has been awarded with the FSEEN 2018 PRIZE

Dr. Belén Peral´s research group has been awarded with the FSEEN 2018 PRIZE  (Spanish Society of Endocrinology and Nutrition) to the best article published in the field of Obesity and Metabolic Syndrome.    In recent years, ageing-associated diseases, including obesity and type 2 diabetes, have been increasingly associated with mitochondrial dysfunction. However, the impact of these conditions on adipose tissue mitochondria remained to be elucidated. Dr. Belén Peral, a biochemist from the Instituto de Investigaciones Biomédicas Alberto Sols, CSIC-UAM (Madrid, Spain) has led a multidisciplinary team that included physicians from two hospitals (Clínico San Carlos and Gregorio Marañón, both from Madrid) and the Laboratory of Cardiovascular Proteomics at the Centro Nacional de Investigaciones Cardiovasculares (CNIC, Madrid),...

Our Masters included in the first places of the 250 Best Masters Ranking 2018 Edition.

The masters given by the Biochemistry Department and the Molecular Biology Department at the UAM are included again in the 250 Best Masters Ranking by the newspaper El Mundo. In this new 2018 edition, the  masters in Biomolecules and Cellular Dynamic  and in Molecular Biomedicine  have  the first and second places, respectively, within the Bioscience area, while the Biotechnology Master is the number one in the speciality of Biotechnology. A basic aspect of the teaching of these masters is the collaboration with the researchers from the IIBM centre (UAM-CSIC), which gives the students the opportunity of being taught in an investigation environment.      http://www.elmundo.es/especiales/mejores-masters/

Dr. Gema Pérez was awarded with Professor Durantez - Foundation L.A.I.R. prize for the best article in the field of immunology carried out in a Spanish laboratory.

On February 15, the Lair Foundation celebrated its 25 th  anniversary. The Lair Foundation is dedicated to the promotion of immunology research and education. Among other activities, the Lair Foundation sponsors the Lair-UAM educational chair. During the ceremony, the 2017 Lair awards were presented.  The Professor Durantez prize for the best article in the field of immunology carried out in a Spanish laboratory was awarded to Gema Pérez Chacón, a member of Juan Manuel Zapata´s group at IIBm, for the work entitled "Indole- 3-Carbinol Synergizes with and Restores Fludarabine Sensitivity in Chronic Lymphocytic Leukemia Cells Irrespective of p53 Activity and Treatment Resistances, "published in Clinical Cancer Research ( Clin Cancer Res.  2016 Jan 1; 22 (1): 134-45). Follow  us on Twitter!

"Constantes y Vitales" Award for the Best Scientific Trajectory goes to Dr Gabriela Morreale de Castro

In the 3rd edition of the awards promoted by "la Sexta"'s corporate responsibility campaign, together with the AXA Foundation, the "Constantes y Vitales" Award for the Best Scientific Trajectory has been awarded to our colleague Dr Gabriela Morreale de Castro , for her multiple contributions to the scientific field related to Endocrinology, especially the role of iodine and thyroid hormones in the development of the fetal and infant brain. The award was presented on October 26 at the Palacio de Neptuno in Madrid by the Secretary of State for Research, Innovation and Development, Ms. Carmen Vela. ATRESMEDIA link    

A researcher from the Neurobiology of Hearing group participates in a clinical trial of a new treatment for hereditary angioedema

Dr. Maria Luisa Baeza from the Neurobiology of Hearing group has participated in a Phase III clinical study ((EudraCT 2013-000916-10, ClinicalTrials.gov NCT01912456) to evaluate the efficacy and safety of the C-1 inhibitor CSL830 in the treatment of hereditary angioedema The results of this trial indicate that the subcutaneous administration of CSL830 decreases the number of attacks of hereditary angioedema per month, with the majority of patients presenting a low profile of side effects. This work has been published in the prestigious New England Journal of Medicine Longhurst et al. Prevention of Hereditary Angioedema Attacks with Subcutaneous C1-Inhibitor. NEJM 2017 Mar 23;376(12):1131-1140  

A new molecule evaluated by the Neurobiology of Hearing group, authorized by the FDA to conduct Phase 1 clinical trial

Biopharmaceutical Company Spiral Therapeutics, Inc. has obtained the authorization from the US Food and Drug Administration (FDA) to start in early 2018 of a phase 1 clinical trial with LPT99, a new molecule for the treatment of chemotherapy-induced hearing loss in pediatric patients. LPT99 is a small molecule with strong anti-apoptotic activity. LPT99 is administered transtympanically in a hydrogel formulation to effectively reach the hair cells in the inner ear. This molecule has confirmed to be safe and effective in the animal model tests carried out by the Neurobiology of Hearing group, within the framework of an agreement with that company that began in 2015 and continues today.